159 related articles for article (PubMed ID: 7510414)
1. Formation of the terminal complement complex on agarose beads: further evidence that vitronectin (complement S-protein) inhibits C9 polymerization.
Johnson E; Berge V; Høgåsen K
Scand J Immunol; 1994 Mar; 39(3):281-5. PubMed ID: 7510414
[TBL] [Abstract][Full Text] [Related]
2. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
[TBL] [Abstract][Full Text] [Related]
3. Clusterin and the terminal complement pathway synthesized by human umbilical vein endothelial cells are closely linked when detected on co-cultured agarose beads.
Berge V; Johnson E; Høgåsen K
APMIS; 1997 Jan; 105(1):17-24. PubMed ID: 9063496
[TBL] [Abstract][Full Text] [Related]
4. S protein binds to serum-treated agarose beads independently of complement activation and the formation of the terminal complement complex on the beads.
Hetland G; Garred P; Pettersen HB; Mollnes TE; Johnson E
Clin Exp Immunol; 1990 Mar; 79(3):459-62. PubMed ID: 1690618
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein.
Podack ER; Preissner KT; Müller-Eberhard HJ
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():89-96. PubMed ID: 6587746
[TBL] [Abstract][Full Text] [Related]
6. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
7. S-protein/vitronectin interaction with the C5b and the C8 of the complement membrane attack complex.
Su HR
Int Arch Allergy Immunol; 1996 Aug; 110(4):314-7. PubMed ID: 8768797
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of complement components C5, C6, C7, C8 and C9 in vitro by human monocytes and assembly of the terminal complement complex.
Hetland G; Johnson E; Falk RJ; Eskeland T
Scand J Immunol; 1986 Oct; 24(4):421-8. PubMed ID: 3764345
[TBL] [Abstract][Full Text] [Related]
9. Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro.
Johnson E; Hetland G
Scand J Immunol; 1991 Jun; 33(6):667-71. PubMed ID: 2047760
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of complement by alveolar macrophages from patients with sarcoidosis.
Pettersen HB; Johnson E; Mollnes TE; Garred P; Hetland G; Osen SS
Scand J Immunol; 1990 Jan; 31(1):15-23. PubMed ID: 1689072
[TBL] [Abstract][Full Text] [Related]
11. Complement inhibition by human vitronectin involves non-heparin binding domains.
Sheehan M; Morris CA; Pussell BA; Charlesworth JA
Clin Exp Immunol; 1995 Jul; 101(1):136-41. PubMed ID: 7542572
[TBL] [Abstract][Full Text] [Related]
12. Terminal complement complex (TCC) and S-protein (vitronectin) on follicular dendritic cells in human lymphoid tissues.
Halstensen TS; Mollnes TE; Brandtzaeg P
Immunology; 1988 Oct; 65(2):193-7. PubMed ID: 2461343
[TBL] [Abstract][Full Text] [Related]
13. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Tschopp J; Chonn A; Hertig S; French LE
J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization.
McDonald JF; Nelsestuen GL
Biochemistry; 1997 Jun; 36(24):7464-73. PubMed ID: 9200695
[TBL] [Abstract][Full Text] [Related]
15. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules.
Kontermann R; Deppisch R; Rauterberg EW
Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659
[TBL] [Abstract][Full Text] [Related]
16. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities.
Tschopp J; Masson D; Schäfer S; Peitsch M; Preissner KT
Biochemistry; 1988 May; 27(11):4103-9. PubMed ID: 2458130
[TBL] [Abstract][Full Text] [Related]
17. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
Hetland G; Bungum L
APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
[TBL] [Abstract][Full Text] [Related]
18. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology.
Mollnes TE; Harboe M
Scand J Immunol; 1987 Oct; 26(4):381-6. PubMed ID: 3685888
[TBL] [Abstract][Full Text] [Related]
20. [Terminal complement complex (TTC) levels in plasma and urine from glomerular diseases: enzyme-linked immunosorbent assay (ELISA) using monoclonal antibody against neoantigens of TCC].
Kusunoki Y
Hokkaido Igaku Zasshi; 1990 Jan; 65(1):74-85. PubMed ID: 2328949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
